Functional beverage enriched with gingerControl beverage without ginger
Functional beverage enriched with ginger: Functional drink enriched with ginger
Control beverage without ginger: Control beverage without ginger
Study summary
Randomized, double-blind, parallel, placebo-controlled clinical trial designed and conducted to evaluate the effect of daily consumption of ginger, on parameters related to inflammation, oxidative stress, and endothelial damage in adults with excess adiposity.
Eligibility
Sex
ALL
Min age
23 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Male and female participants.
* Age between 23 and 65 years.
* Body mass index (BMI) \> 27.5 kg/m².
* Absence of diagnosed chronic diseases.
* Not receiving pharmacological treatment or dietary supplementation on a regular basis.
* Ability to understand the study procedures and willingness to comply with study requirements.
Exclusion Criteria:
* Presence of acute or chronic diseases not specified in the inclusion criteria.
* Ongoing chronic pharmacological treatment or active use of dietary supplements.
* Major surgery within the previous three months.
* Current smokers or recent former smokers (less than six months since cessation).
* History of clinically relevant food allergies or eating disorders.
* Concurrent participation in another clinical trial or research study.
* Pregnancy or breastfeeding.
* Following an active weight-loss diet.
* Investigator's judgment of unsuitability for study participation.
Primary outcome measure(s)
Change in serum interleukin-1 beta (IL-1β) levels — Day 1 and Day 60 Evaluation on differences in serum IL-1β levels
Change in serum interleukin-6 (IL-6) levels — Day 1 and Day 60 Evaluation on differences in serum IL-6 levels
Change in plasma homocysteine levels — Day 1 and Day 60 Evaluation on differences in homocysteine levels
Change in plasma fibrinogen concentrations — Day 1 and Day 60 Evaluation on differences in fibrinogen concentrations
Atherogenic index — Day 1 and Day 60 Evaluation on differences in atherogenic index. Differences in the Atherogenic Index of Plasma (AIP), calculated as log (triglycerides/HDL-cholesterol), will be evaluated between the intervention and control groups. Additionally, pre-post changes in AIP will be assessed within each group.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.